AMRX Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc. (AMRX) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $3.7M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Kiely John | Director | Sell | 50,000 | $17.64 | $882.0K | 210,252 −19.2% of holding | |
| Daly Jason B. | EVP, Chief Legal Officer | Sell | 210,000 | $17.40 | $3.7M | 35,171 −85.7% of holding | |
| Shah Nikita | Executive Vice President | Sell | 146,403 | $17.51 | $2.6M | 253,390 −36.6% of holding | |
| Daly Jason B. | EVP, Chief Legal Officer | Sell | 6,613 | $17.70 | $117.1K | 245,171 −2.6% of holding | |
| Autor Deborah M. | Director | Sell | 34,819 | $12.94 | $450.6K | 93,660 −27.1% of holding | |
| Nark Ted C | Director | Sell | 50,000 | $11.72 | $586.0K | 291,029 −14.7% of holding | |
| Shah Nikita | Executive Vice President | Sell | 131,856 | $11.92 | $1.6M | 146,403 −47.4% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.